nodes	percent_of_prediction	percent_of_DWPC	metapath
Fosaprepitant—Postnasal drip—Varenicline—nicotine dependence	0.0953	0.102	CcSEcCtD
Fosaprepitant—Upper-airway cough syndrome—Varenicline—nicotine dependence	0.0807	0.0867	CcSEcCtD
Fosaprepitant—Sensory disturbance—Varenicline—nicotine dependence	0.0475	0.051	CcSEcCtD
Fosaprepitant—Polydipsia—Varenicline—nicotine dependence	0.0475	0.051	CcSEcCtD
Fosaprepitant—Throat irritation—Varenicline—nicotine dependence	0.0292	0.0314	CcSEcCtD
Fosaprepitant—Upset stomach—Varenicline—nicotine dependence	0.0225	0.0242	CcSEcCtD
Fosaprepitant—Glycosuria—Varenicline—nicotine dependence	0.0182	0.0195	CcSEcCtD
Fosaprepitant—Chest discomfort—Varenicline—nicotine dependence	0.0167	0.0179	CcSEcCtD
Fosaprepitant—Gastrooesophageal reflux disease—Varenicline—nicotine dependence	0.0163	0.0175	CcSEcCtD
Fosaprepitant—Dysarthria—Varenicline—nicotine dependence	0.0156	0.0167	CcSEcCtD
Fosaprepitant—Blood pressure increased—Varenicline—nicotine dependence	0.0147	0.0158	CcSEcCtD
Fosaprepitant—Eructation—Varenicline—nicotine dependence	0.0145	0.0155	CcSEcCtD
Fosaprepitant—Urine output increased—Varenicline—nicotine dependence	0.0133	0.0143	CcSEcCtD
Fosaprepitant—Euphoric mood—Varenicline—nicotine dependence	0.0127	0.0136	CcSEcCtD
Fosaprepitant—Disorientation—Varenicline—nicotine dependence	0.012	0.0128	CcSEcCtD
Fosaprepitant—Hot flush—Varenicline—nicotine dependence	0.0114	0.0123	CcSEcCtD
Fosaprepitant—Menopausal symptoms—Varenicline—nicotine dependence	0.0113	0.0122	CcSEcCtD
Fosaprepitant—Lethargy—Varenicline—nicotine dependence	0.0109	0.0117	CcSEcCtD
Fosaprepitant—Osteoarthritis—Varenicline—nicotine dependence	0.0107	0.0115	CcSEcCtD
Fosaprepitant—Abdominal pain upper—Varenicline—nicotine dependence	0.00977	0.0105	CcSEcCtD
Fosaprepitant—Hypokalaemia—Varenicline—nicotine dependence	0.00974	0.0105	CcSEcCtD
Fosaprepitant—TACR1—Peptide GPCRs—OPRM1—nicotine dependence	0.00968	0.141	CbGpPWpGaD
Fosaprepitant—Abdominal distension—Varenicline—nicotine dependence	0.00931	0.01	CcSEcCtD
Fosaprepitant—Abdominal discomfort—Varenicline—nicotine dependence	0.00887	0.00952	CcSEcCtD
Fosaprepitant—Pollakiuria—Varenicline—nicotine dependence	0.00854	0.00917	CcSEcCtD
Fosaprepitant—Photosensitivity reaction—Varenicline—nicotine dependence	0.00844	0.00906	CcSEcCtD
Fosaprepitant—Infestation NOS—Varenicline—nicotine dependence	0.00825	0.00885	CcSEcCtD
Fosaprepitant—Infestation—Varenicline—nicotine dependence	0.00825	0.00885	CcSEcCtD
Fosaprepitant—Stevens-Johnson syndrome—Varenicline—nicotine dependence	0.00817	0.00878	CcSEcCtD
Fosaprepitant—Stomatitis—Varenicline—nicotine dependence	0.00804	0.00863	CcSEcCtD
Fosaprepitant—Conjunctivitis—Varenicline—nicotine dependence	0.00801	0.00861	CcSEcCtD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—CHRNB4—nicotine dependence	0.00781	0.114	CbGpPWpGaD
Fosaprepitant—Bradycardia—Varenicline—nicotine dependence	0.00754	0.00809	CcSEcCtD
Fosaprepitant—Hypoaesthesia—Varenicline—nicotine dependence	0.00736	0.00791	CcSEcCtD
Fosaprepitant—Urinary tract disorder—Varenicline—nicotine dependence	0.00731	0.00785	CcSEcCtD
Fosaprepitant—Connective tissue disorder—Varenicline—nicotine dependence	0.00727	0.00781	CcSEcCtD
Fosaprepitant—Urethral disorder—Varenicline—nicotine dependence	0.00726	0.00779	CcSEcCtD
Fosaprepitant—Erythema multiforme—Varenicline—nicotine dependence	0.007	0.00751	CcSEcCtD
Fosaprepitant—Eye disorder—Varenicline—nicotine dependence	0.00692	0.00743	CcSEcCtD
Fosaprepitant—Tinnitus—Varenicline—nicotine dependence	0.0069	0.00741	CcSEcCtD
Fosaprepitant—Cardiac disorder—Varenicline—nicotine dependence	0.00687	0.00738	CcSEcCtD
Fosaprepitant—Angiopathy—Varenicline—nicotine dependence	0.00672	0.00721	CcSEcCtD
Fosaprepitant—Immune system disorder—Varenicline—nicotine dependence	0.00669	0.00718	CcSEcCtD
Fosaprepitant—Mediastinal disorder—Varenicline—nicotine dependence	0.00667	0.00716	CcSEcCtD
Fosaprepitant—Mental disorder—Varenicline—nicotine dependence	0.00648	0.00696	CcSEcCtD
Fosaprepitant—Erythema—Varenicline—nicotine dependence	0.00644	0.00692	CcSEcCtD
Fosaprepitant—Malnutrition—Varenicline—nicotine dependence	0.00644	0.00692	CcSEcCtD
Fosaprepitant—Flatulence—Varenicline—nicotine dependence	0.00635	0.00682	CcSEcCtD
Fosaprepitant—Dysgeusia—Varenicline—nicotine dependence	0.00631	0.00677	CcSEcCtD
Fosaprepitant—Muscle spasms—Varenicline—nicotine dependence	0.00619	0.00665	CcSEcCtD
Fosaprepitant—Ill-defined disorder—Varenicline—nicotine dependence	0.00598	0.00642	CcSEcCtD
Fosaprepitant—Anaemia—Varenicline—nicotine dependence	0.00596	0.00639	CcSEcCtD
Fosaprepitant—Angioedema—Varenicline—nicotine dependence	0.00589	0.00632	CcSEcCtD
Fosaprepitant—Malaise—Varenicline—nicotine dependence	0.00581	0.00624	CcSEcCtD
Fosaprepitant—Syncope—Varenicline—nicotine dependence	0.00578	0.0062	CcSEcCtD
Fosaprepitant—Palpitations—Varenicline—nicotine dependence	0.00569	0.00611	CcSEcCtD
Fosaprepitant—Loss of consciousness—Varenicline—nicotine dependence	0.00566	0.00608	CcSEcCtD
Fosaprepitant—Cough—Varenicline—nicotine dependence	0.00562	0.00604	CcSEcCtD
Fosaprepitant—Hypertension—Varenicline—nicotine dependence	0.00556	0.00597	CcSEcCtD
Fosaprepitant—TACR1—GPCR ligand binding—TAS2R16—nicotine dependence	0.00552	0.0803	CbGpPWpGaD
Fosaprepitant—Chest pain—Varenicline—nicotine dependence	0.00549	0.00589	CcSEcCtD
Fosaprepitant—Anxiety—Varenicline—nicotine dependence	0.00547	0.00587	CcSEcCtD
Fosaprepitant—Unspecified disorder of skin and subcutaneous tissue—Varenicline—nicotine dependence	0.00545	0.00585	CcSEcCtD
Fosaprepitant—Discomfort—Varenicline—nicotine dependence	0.00542	0.00582	CcSEcCtD
Fosaprepitant—Dry mouth—Varenicline—nicotine dependence	0.00536	0.00576	CcSEcCtD
Fosaprepitant—Oedema—Varenicline—nicotine dependence	0.00526	0.00565	CcSEcCtD
Fosaprepitant—Infection—Varenicline—nicotine dependence	0.00522	0.00561	CcSEcCtD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—CHRNB2—nicotine dependence	0.00521	0.0759	CbGpPWpGaD
Fosaprepitant—Shock—Varenicline—nicotine dependence	0.00517	0.00555	CcSEcCtD
Fosaprepitant—Nervous system disorder—Varenicline—nicotine dependence	0.00516	0.00554	CcSEcCtD
Fosaprepitant—Skin disorder—Varenicline—nicotine dependence	0.00511	0.00548	CcSEcCtD
Fosaprepitant—Hyperhidrosis—Varenicline—nicotine dependence	0.00508	0.00546	CcSEcCtD
Fosaprepitant—Hypotension—Varenicline—nicotine dependence	0.00491	0.00528	CcSEcCtD
Fosaprepitant—Insomnia—Varenicline—nicotine dependence	0.00476	0.00511	CcSEcCtD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—CHRNA4—nicotine dependence	0.00473	0.0689	CbGpPWpGaD
Fosaprepitant—Dyspnoea—Varenicline—nicotine dependence	0.00469	0.00503	CcSEcCtD
Fosaprepitant—Somnolence—Varenicline—nicotine dependence	0.00467	0.00502	CcSEcCtD
Fosaprepitant—Dyspepsia—Varenicline—nicotine dependence	0.00463	0.00497	CcSEcCtD
Fosaprepitant—Decreased appetite—Varenicline—nicotine dependence	0.00457	0.00491	CcSEcCtD
Fosaprepitant—TACR1—Peptide ligand-binding receptors—OPRM1—nicotine dependence	0.00455	0.0663	CbGpPWpGaD
Fosaprepitant—Gastrointestinal disorder—Varenicline—nicotine dependence	0.00454	0.00487	CcSEcCtD
Fosaprepitant—Fatigue—Varenicline—nicotine dependence	0.00453	0.00487	CcSEcCtD
Fosaprepitant—Pain—Varenicline—nicotine dependence	0.0045	0.00483	CcSEcCtD
Fosaprepitant—Constipation—Varenicline—nicotine dependence	0.0045	0.00483	CcSEcCtD
Fosaprepitant—Feeling abnormal—Varenicline—nicotine dependence	0.00433	0.00465	CcSEcCtD
Fosaprepitant—Gastrointestinal pain—Varenicline—nicotine dependence	0.0043	0.00462	CcSEcCtD
Fosaprepitant—Urticaria—Varenicline—nicotine dependence	0.00418	0.00449	CcSEcCtD
Fosaprepitant—Abdominal pain—Varenicline—nicotine dependence	0.00416	0.00446	CcSEcCtD
Fosaprepitant—Body temperature increased—Varenicline—nicotine dependence	0.00416	0.00446	CcSEcCtD
Fosaprepitant—Hypersensitivity—Varenicline—nicotine dependence	0.00387	0.00416	CcSEcCtD
Fosaprepitant—Asthenia—Varenicline—nicotine dependence	0.00377	0.00405	CcSEcCtD
Fosaprepitant—Pruritus—Varenicline—nicotine dependence	0.00372	0.00399	CcSEcCtD
Fosaprepitant—Diarrhoea—Varenicline—nicotine dependence	0.0036	0.00386	CcSEcCtD
Fosaprepitant—Dizziness—Varenicline—nicotine dependence	0.00348	0.00373	CcSEcCtD
Fosaprepitant—Vomiting—Varenicline—nicotine dependence	0.00334	0.00359	CcSEcCtD
Fosaprepitant—Rash—Varenicline—nicotine dependence	0.00332	0.00356	CcSEcCtD
Fosaprepitant—Dermatitis—Varenicline—nicotine dependence	0.00331	0.00356	CcSEcCtD
Fosaprepitant—Headache—Varenicline—nicotine dependence	0.00329	0.00354	CcSEcCtD
Fosaprepitant—Nausea—Varenicline—nicotine dependence	0.00312	0.00335	CcSEcCtD
Fosaprepitant—TACR1—GPCR downstream signaling—TAS2R16—nicotine dependence	0.00312	0.0454	CbGpPWpGaD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.00305	0.0445	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—TAS2R16—nicotine dependence	0.00283	0.0412	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—FGD1—nicotine dependence	0.00245	0.0356	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—OPRM1—nicotine dependence	0.00232	0.0339	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—FGD1—nicotine dependence	0.00222	0.0323	CbGpPWpGaD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.00221	0.0321	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—DRD2—nicotine dependence	0.00168	0.0245	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—TAS2R16—nicotine dependence	0.00167	0.0244	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—OPRM1—nicotine dependence	0.00131	0.0191	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—FGD1—nicotine dependence	0.00131	0.0191	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—OPRM1—nicotine dependence	0.00119	0.0174	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—AKR1B10—nicotine dependence	0.00116	0.0169	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—DRD2—nicotine dependence	0.00095	0.0138	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—DRD2—nicotine dependence	0.000863	0.0126	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—WASF2—nicotine dependence	0.000816	0.0119	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—WASF1—nicotine dependence	0.000783	0.0114	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—OPRM1—nicotine dependence	0.000705	0.0103	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—DRD2—nicotine dependence	0.00051	0.00742	CbGpPWpGaD
